Compare NHPAP & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
National Healthcare Properties Inc. 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock
Current Price
Current Price
| Metric | NHPAP | ICUCW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 26 | 18 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | 2021 |
| Metric | NHPAP | ICUCW |
|---|---|---|
| Price | $19.21 | $0.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | N/A |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | N/A |
| 52 Week High | N/A | N/A |
| Indicator | NHPAP | ICUCW |
|---|---|---|
| Relative Strength Index (RSI) | 51.04 | 35.62 |
| Support Level | $18.88 | $0.01 |
| Resistance Level | $19.46 | $0.01 |
| Average True Range (ATR) | 0.23 | 0.00 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 17.85 | 24.56 |
National Healthcare Properties Inc is a publicly registered real estate investment trust focused on acquiring a diversified portfolio of healthcare real estate, with an emphasis on seniors housing operating properties (SHOP) and outpatient medical facilities (OMF), located in the United States. The company has SHOPs and OMFs as two reportable business segments for management and internal financial reporting purposes. OMF consists of physicians' offices and examination rooms, hospitals, pharmacies, other facilities. SHOP consist of assisted living facilities, memory care facilities, Independent Living facilities. Majority of revenue is from OMFs segment.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.